Finally, higher proportions of tumor-reactive T cells co-expressing CCL4, IFN-γ, and TNF-α were detected in melanoma patients with favorable clinical responses to α-CTLA-4 treatment [34]. The gene discussed is CTLA4; the disease is neoplasm.